Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway

Objective(s): Psoriasis is an autoimmune disease that mainly affects the skin and joints, which is mediated via T-cells. Several factors contribute to its pathogenesis, including genetic and environmental triggers, as well as intrinsic immune processes that lead to an autoimmune response. Silymarin,...

Descripción completa

Detalles Bibliográficos
Autores: Azimi, Behnaz, Kiani, Amir, Noori, Tayebeh, Sureda, Antoni, Shirooie, Samira
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/25999
Acceso en línea:https://hdl.handle.net/20.500.13003/25999
Access Level:acceso abierto
Palabra clave:Imiquimod
Inflammation
Mice
Male
Psoriasis
Dermatology
Silymarin
NF-kappa B
Administration, Topical
Skin
Antioxidants
Medication Adherence
Rats
Inflamación
Ratones
Masculino
Dermatología
Silimarina
FN-kappa B
Administración Tópica
Piel
Antioxidantes
Cumplimiento de la Medicación
Ratas
Male mice
id ES_e4e0b5567c8d3cdba28ad33bb4c5d2f3
oai_identifier_str oai:docusalut.com:20.500.13003/25999
network_acronym_str ES
network_name_str España
repository_id_str
spelling Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathwayAzimi, BehnazKiani, AmirNoori, TayebehSureda, AntoniShirooie, SamiraImiquimodInflammationMiceMalePsoriasisDermatologySilymarinNF-kappa BAdministration, TopicalSkinAntioxidantsMedication AdherenceRatsImiquimodInflamaciónRatonesMasculinoPsoriasisDermatologíaSilimarinaFN-kappa BAdministración TópicaPielAntioxidantesCumplimiento de la MedicaciónRatasImiquimodInflammationMale micePsoriasisSilymarinObjective(s): Psoriasis is an autoimmune disease that mainly affects the skin and joints, which is mediated via T-cells. Several factors contribute to its pathogenesis, including genetic and environmental triggers, as well as intrinsic immune processes that lead to an autoimmune response. Silymarin, a flavonoid complex extracted from Silybum marianum, exhibits anti-inflammatory, immunostimulatory, and anti-oxidant properties, rendering it a viable candidate for treating psoriasis. This study aimed to investigate the effect of silymarin on imiquimod (IMQ) induced psoriasis-like skin lesions in male mice applied as a cream for seven consecutive days (1 mg per mouse). Materials and Methods: Thirty-five male mice were assigned to seven groups (n=5 per group): (I) control group, (II) IMQ group, (III-V) oral silymarin groups (30, 60, and 120 mg/kg), (VI) topical betamethasone group, and (VII) topical silymarin 2% group. Results: Silymarin, both orally and topically, significantly reduces erythema, thickness, and scaling induced by IMQ after seven days of treatment. The treatment also reversed the increase in spleen weight/body weight ratio. Immunofluorescence analysis revealed that silymarin reduced the expression of nuclear factor kappa B (NF-kappa B) (P<0.01) and toll-like receptor 4 (TLR4) (P<0.01) compared to the IMQ group. Conclusion: These findings suggest that silymarin effectively alleviates psoriasis lesions by reducing inflammation and modulating the TLR4/ NF-kappa B signaling pathway.20252025-01-0120252025-01-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/25999reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/259992026-06-22T12:44:07Z
dc.title.none.fl_str_mv Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway
title Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway
spellingShingle Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway
Azimi, Behnaz
Imiquimod
Inflammation
Mice
Male
Psoriasis
Dermatology
Silymarin
NF-kappa B
Administration, Topical
Skin
Antioxidants
Medication Adherence
Rats
Imiquimod
Inflamación
Ratones
Masculino
Psoriasis
Dermatología
Silimarina
FN-kappa B
Administración Tópica
Piel
Antioxidantes
Cumplimiento de la Medicación
Ratas
Imiquimod
Inflammation
Male mice
Psoriasis
Silymarin
title_short Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway
title_full Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway
title_fullStr Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway
title_full_unstemmed Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway
title_sort Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway
dc.creator.none.fl_str_mv Azimi, Behnaz
Kiani, Amir
Noori, Tayebeh
Sureda, Antoni
Shirooie, Samira
author Azimi, Behnaz
author_facet Azimi, Behnaz
Kiani, Amir
Noori, Tayebeh
Sureda, Antoni
Shirooie, Samira
author_role author
author2 Kiani, Amir
Noori, Tayebeh
Sureda, Antoni
Shirooie, Samira
author2_role author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Imiquimod
Inflammation
Mice
Male
Psoriasis
Dermatology
Silymarin
NF-kappa B
Administration, Topical
Skin
Antioxidants
Medication Adherence
Rats
Imiquimod
Inflamación
Ratones
Masculino
Psoriasis
Dermatología
Silimarina
FN-kappa B
Administración Tópica
Piel
Antioxidantes
Cumplimiento de la Medicación
Ratas
Imiquimod
Inflammation
Male mice
Psoriasis
Silymarin
topic Imiquimod
Inflammation
Mice
Male
Psoriasis
Dermatology
Silymarin
NF-kappa B
Administration, Topical
Skin
Antioxidants
Medication Adherence
Rats
Imiquimod
Inflamación
Ratones
Masculino
Psoriasis
Dermatología
Silimarina
FN-kappa B
Administración Tópica
Piel
Antioxidantes
Cumplimiento de la Medicación
Ratas
Imiquimod
Inflammation
Male mice
Psoriasis
Silymarin
description Objective(s): Psoriasis is an autoimmune disease that mainly affects the skin and joints, which is mediated via T-cells. Several factors contribute to its pathogenesis, including genetic and environmental triggers, as well as intrinsic immune processes that lead to an autoimmune response. Silymarin, a flavonoid complex extracted from Silybum marianum, exhibits anti-inflammatory, immunostimulatory, and anti-oxidant properties, rendering it a viable candidate for treating psoriasis. This study aimed to investigate the effect of silymarin on imiquimod (IMQ) induced psoriasis-like skin lesions in male mice applied as a cream for seven consecutive days (1 mg per mouse). Materials and Methods: Thirty-five male mice were assigned to seven groups (n=5 per group): (I) control group, (II) IMQ group, (III-V) oral silymarin groups (30, 60, and 120 mg/kg), (VI) topical betamethasone group, and (VII) topical silymarin 2% group. Results: Silymarin, both orally and topically, significantly reduces erythema, thickness, and scaling induced by IMQ after seven days of treatment. The treatment also reversed the increase in spleen weight/body weight ratio. Immunofluorescence analysis revealed that silymarin reduced the expression of nuclear factor kappa B (NF-kappa B) (P<0.01) and toll-like receptor 4 (TLR4) (P<0.01) compared to the IMQ group. Conclusion: These findings suggest that silymarin effectively alleviates psoriasis lesions by reducing inflammation and modulating the TLR4/ NF-kappa B signaling pathway.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025-01-01
2025
2025-01-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/25999
url https://hdl.handle.net/20.500.13003/25999
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422630199623680
score 15.811543

Similares en LA Referencia